We are live on ! Find out more
OMIC

Singular Genomics Systems, Inc. Common Stock

Delisted

OMIC was delisted on the 20th of February, 2025.

74 hedge funds and large institutions have $99.2M invested in Singular Genomics Systems, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 25 increasing their positions, 19 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

32% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 19

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

3% less funds holding

Funds holding: 7674 (-2)

14% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 14

33% less capital invested

Capital invested by funds: $147M → $99.2M (-$47.8M)

Holders
74
Holders Change
-2
Holders Change %
-2.63%
% of All Funds
1.27%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
12
Increased
25
Reduced
19
Closed
14
Calls
Puts
Net Calls
Net Calls Change

OMIC Hedge Fund Activity: Q3 2022 in Review

74 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Singular Genomics Systems, Inc. Common Stock (OMIC) for Q3 2022, worth a combined $99.2M — down 33% from $147M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of OMIC and 12 opened new positions — a net loss of 2 holders — while 19 trimmed existing stakes and 25 added.

The largest buyer was Deerfield Management, adding an estimated $2.58M. The largest seller was Alphabet Inc, exiting entirely with an estimated $2.24M sold.

  • 74 institutional investors held Singular Genomics Systems, Inc. Common Stock (OMIC) as of Q3 2022, down from 76 in Q2 2022.
  • Funds reported $99.2M of Singular Genomics Systems, Inc. Common Stock stock for Q3 2022, down 33% quarter-over-quarter.
  • 12 funds opened new Singular Genomics Systems, Inc. Common Stock positions in Q3 2022 and 14 closed out, a net change of -2 holders.
  • The largest Singular Genomics Systems, Inc. Common Stock buyer in Q3 2022 was Deerfield Management, an estimated $2.58M added.
  • The largest Singular Genomics Systems, Inc. Common Stock seller in Q3 2022 was Alphabet Inc, an estimated $2.24M sold.

Based on aggregated 13F filings for Q3 2022.